Shares of Histogenics Corp (NASDAQ:HSGX) gapped down prior to trading on Friday . The stock had previously closed at $0.78, but opened at $0.67. Histogenics shares last traded at $0.55, with a volume of 6683500 shares trading hands.
A number of brokerages recently issued reports on HSGX. Brookline Cap M reiterated a “buy” rating on shares of Histogenics in a report on Wednesday, August 1st. HC Wainwright reissued a “buy” rating and issued a $3.50 price objective on shares of Histogenics in a research note on Monday, August 13th. Zacks Investment Research raised shares of Histogenics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Thursday, July 12th. Needham & Company LLC boosted their price objective on shares of Histogenics to $5.00 and gave the stock a “buy” rating in a research note on Thursday, September 6th. Finally, BTIG Research downgraded shares of Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price objective for the company. in a research note on Wednesday, September 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Histogenics presently has a consensus rating of “Hold” and a consensus target price of $3.45.
The company has a market capitalization of $16.12 million, a P/E ratio of -0.56 and a beta of 1.02.
A number of large investors have recently modified their holdings of HSGX. BlackRock Inc. raised its stake in Histogenics by 72.0% in the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after buying an additional 22,927 shares in the last quarter. DRW Securities LLC acquired a new position in shares of Histogenics during the second quarter worth $242,000. JPMorgan Chase & Co. acquired a new position in shares of Histogenics during the first quarter worth $320,000. Finally, Renaissance Technologies LLC increased its position in shares of Histogenics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 22,133 shares in the last quarter. 45.88% of the stock is owned by institutional investors.
About Histogenics (NASDAQ:HSGX)
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Further Reading: What is a stock split?
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.